

Diana Ferraro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9488130/publications.pdf>

Version: 2024-02-01

110
papers

2,661
citations

185998

28
h-index

233125

45
g-index

113
all docs

113
docs citations

113
times ranked

3232
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. <i>Journal of Neurology</i> , 2022, 269, 1463-1469.	1.8	4
2	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	0.9	53
3	Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus. <i>Epilepsia</i> , 2022, 63, e23.	2.6	14
4	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	31
5	Detection of Neurofilament Light Chain with Label-Free Electrolyte-Gated Organic Field-Effect Transistors. <i>Advanced Materials Interfaces</i> , 2022, 9, .	1.9	9
6	Oligoclonal bands: clinical utility and interpretation cues. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 391-404.	2.7	15
7	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	1.4	2
8	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	1.7	3
9	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. <i>Biomolecules</i> , 2022, 12, 677.	1.8	2
10	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	1.7	1
11	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11
12	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021, 27, 695-705.	1.4	7
13	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	1.4	19
14	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
15	A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis. <i>Neurological Sciences</i> , 2021, 42, 1941-1947.	0.9	3
16	Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 269-277.	1.7	1
17	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. <i>Neuroepidemiology</i> , 2021, 55, 224-231.	1.1	4
18	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Microglia activation: a role for mitochondrial DNA?. <i>Neural Regeneration Research</i> , 2021, 16, 2393.	1.6	8
20	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021, 18, 1166-1174.	2.1	24
21	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117430.	0.3	1
22	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	4.5	26
23	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
24	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
25	Efficacy of mechanical thrombectomy in patients with ischemic stroke and cancer. <i>Journal of Clinical Neuroscience</i> , 2021, 91, 20-22.	0.8	15
26	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
27	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.3	9
28	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
29	Inter-center agreement in the interpretation of oligoclonal bands. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e91-e94.	1.4	4
30	Brain volume measures in adults with MOG-antibody associated disease: A longitudinal multicentre study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118108.	0.3	0
31	Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients. <i>Cells</i> , 2021, 10, 3324.	1.8	3
32	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.	0.9	14
33	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
34	Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 16-21.	1.0	33
35	Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 461-467.	1.7	26
36	Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 338, 577107.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	0.9	29
38	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
39	Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia. <i>Molecular and Cellular Neurosciences</i> , 2020, 108, 103538.	1.0	15
40	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	0.9	2
41	Kappa Index versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders. <i>Diagnostics</i> , 2020, 10, 856.	1.3	19
42	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	4.5	21
43	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
44	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
45	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	4.9	219
46	Cell-based assays for the detection of MOG antibodies: a comparative study. <i>Journal of Neurology</i> , 2020, 267, 3555-3564.	1.8	44
47	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	0.9	0
48	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. <i>Neurology: Clinical Practice</i> , 2020, 10, 510-519.	0.8	17
49	Diagnostic features of initial demyelinating events associated with serum MOG-IgG. <i>Journal of Neuroimmunology</i> , 2020, 344, 577260.	1.1	0
50	Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients. <i>European Journal of Immunology</i> , 2019, 49, 2204-2221.	1.6	24
51	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.	1.1	21
52	Cerebrospinal fluid free light chains determination in oligoclonal bands negative patients with suspected multiple sclerosis. <i>Clinica Chimica Acta</i> , 2019, 493, S616-S617.	0.5	0
53	The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 146-152.	0.9	13
54	“Better explanations” in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.	1.5	44

#	ARTICLE	IF	CITATIONS
55	Abnormal Circadian Modification of A α -Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome. <i>Pain Research and Management</i> , 2019, 2019, 1-8.	0.7	3
56	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
57	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	0.9	35
58	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
59	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	1.7	12
60	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. <i>Journal of Neurology</i> , 2018, 265, 424-430.	1.8	21
61	Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. <i>Neurology</i> , 2018, 90, 852-854.	1.5	13
62	First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. <i>Current Medical Research and Opinion</i> , 2018, 34, 1803-1807.	0.9	13
63	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	1.4	36
64	Systematic assessment and characterization of chronic pain in multiple sclerosis patients. <i>Neurological Sciences</i> , 2018, 39, 445-453.	0.9	39
65	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.3	22
66	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	4.5	20
67	Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 233-242.	1.1	34
68	Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. <i>Immunology Letters</i> , 2017, 183, 1-7.	1.1	36
69	Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1864-1873.	0.7	14
70	Definitive childlessness in women with multiple sclerosis: a multicenter study. <i>Neurological Sciences</i> , 2017, 38, 1453-1459.	0.9	35
71	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. <i>Journal of Neurology</i> , 2017, 264, 973-978.	1.8	18
72	Diagnostics of anti-MAG antibody polyneuropathy. <i>Neurological Sciences</i> , 2017, 38, 249-252.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Diagnostics of dysimmune peripheral neuropathies. <i>Neurological Sciences</i> , 2017, 38, 243-247.	0.9	8
74	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.5	38
75	Acute hemichorea as unusual first multiple sclerosis presentation. <i>Neurology: Clinical Practice</i> , 2017, 7, e9-e11.	0.8	1
76	Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome. <i>Journal of NeuroVirology</i> , 2017, 23, 329-334.	1.0	3
77	iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. <i>Frontiers in Immunology</i> , 2016, 7, 555.	2.2	27
78	Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. <i>European Journal of Neurology</i> , 2016, 23, 1426-1432.	1.7	21
79	Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 245-249.	1.4	11
80	Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses. <i>Neurologist</i> , 2015, 19, 153-154.	0.4	10
81	Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis. <i>Journal of Neuroimmunology</i> , 2015, 283, 64-69.	1.1	48
82	Severe anemia in a patient with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2014, 83, 374-375.	1.5	6
83	Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. <i>Current Medical Research and Opinion</i> , 2014, 30, 1849-1855.	0.9	17
84	False positive absent somatosensory evoked potentials in cardiac arrest with therapeutic hypothermia. <i>Resuscitation</i> , 2014, 85, e183-e184.	1.3	5
85	Aging with HIV infection: A journey to the center of inflammAIDS, immunosenescence and neuroHIV. <i>Immunology Letters</i> , 2014, 162, 329-333.	1.1	59
86	Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. <i>Journal of Neuroimmunology</i> , 2013, 257, 76-81.	1.1	53
87	Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker. <i>Neurological Sciences</i> , 2013, 34, 769-771.	0.9	7
88	Recurrent Varicella following Steroids and Fingolimod in a Multiple Sclerosis Patient. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1059-1061.	2.1	6
89	Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1550-1550.	1.4	2
90	Paroxysmal ventricular tachycardia and pure right insular stroke. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 842-843.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Habituation to Pain in "Medication Overuse Headache": A CO ₂ Laser-Evoked Potential Study. <i>Headache</i> , 2012, 52, 792-807.	1.8	40
92	Evidence of different spinal pathways for the warmth evoked potentials. <i>Clinical Neurophysiology</i> , 2011, 122, 2469-2474.	0.7	5
93	Semiautomated segmentation of the human spine based on echoplanar images. <i>Magnetic Resonance Imaging</i> , 2011, 29, 1429-1436.	1.0	8
94	Isolated progressive cognitive impairment and depression in a patient with neuroradiological features suggestive of multiple sclerosis. <i>Neurological Sciences</i> , 2011, 32, 695-697.	0.9	0
95	Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 451-457.	2.3	38
96	Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. <i>Multiple Sclerosis Journal</i> , 2011, 17, 303-311.	1.4	34
97	Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study. <i>Pain</i> , 2010, 149, 379-385.	2.0	40
98	The Abnormal Recovery Cycle of Somatosensory Evoked Potential Components in Children with Migraine can be Reversed by Topiramate. <i>Cephalalgia</i> , 2010, 30, 17-26.	1.8	27
99	A quantitative comparison of BOLD fMRI responses to noxious and innocuous stimuli in the human spinal cord. <i>NeuroImage</i> , 2010, 50, 1408-1415.	2.1	55
100	Topiramate in the prevention of pediatric migraine: literature review. <i>Journal of Headache and Pain</i> , 2008, 9, 147-150.	2.5	31
101	Letter to Editor: Carpal tunnel syndrome due to an atypical deep soft tissue leiomyoma: The risk of misdiagnosis and mismanagement. <i>World Journal of Surgical Oncology</i> , 2008, 6, 22.	0.8	2
102	PO.12 INTESTINAL PERMEABILITY IN MIGRAINEURS. <i>Digestive and Liver Disease</i> , 2008, 40, S175.	0.4	0
103	Left thalamomegaly in a patient with partial epilepsy. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 298-301.	0.6	1
104	Acute necrotizing encephalopathy: a relapsing case in a European adult. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 227-228.	0.9	15
105	Antiepileptic drugs in the preventive treatment of migraine in children and adolescents. <i>Drug Development Research</i> , 2007, 68, 355-359.	1.4	3
106	Topiramate and Triptans Revert Chronic Migraine With Medication Overuse to Episodic Migraine. <i>Clinical Neuropharmacology</i> , 2006, 29, 269-275.	0.2	64
107	Multiple attack study on the available triptans in Italy versus placebo. <i>European Journal of Neurology</i> , 2005, 12, 557-563.	1.7	11
108	Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. <i>Neurological Sciences</i> , 2004, 25, 245-250.	0.9	65

#	ARTICLE	IF	CITATIONS
109	Antiepileptic drugs in the treatment of headache: neuroprotective effect or something else?. Journal of Headache and Pain, 2004, 5, s117-s120.	2.5	1
110	Occupational head injury and subsequent glioma. Neurological Sciences, 2003, 24, 31-33.	0.9	15